Clinical Evaluation of an Innovative CaHA Bio-Stimulator in Facial Rejuvenation: 1 Year Follow-Up.

BACKGROUND

Skin aging is characterized by wrinkles, loss of elasticity, laxity, and rough texture, resulting from degenerative changes in the skin's layers. Effective treatments targeting skin structure are increasingly sought after in aesthetic medicine.

AIMS

This study aimed to evaluate the safety, efficacy, and long-term outcomes of STIIM, a novel calcium hydroxylapatite (CaHA)-based bio-stimulator, in facial rejuvenation.

PATIENTS/METHODS: Thirty-two patients aged 35-59 received diluted CaHA injections. Outcomes were assessed through patient satisfaction surveys and objective measurements, including ultrasound evaluation of dermal thickness. Follow-ups were conducted at 120 and 360 days post-procedure. Safety was evaluated by monitoring adverse events.

RESULTS

At 120 days post-treatment, 85% of patients reported visible aesthetic improvements, and ultrasound assessments in a subset of patients demonstrated a significant 51% increase in dermal thickness, indicating improved skin structure. At 360 days, 75% of the patients continued to report aesthetic benefits, confirming the durability of the results. The treatment was well-tolerated, with no serious adverse events reported throughout the study period.

CONCLUSIONS

This novel CaHA-based bio-stimulator demonstrates a safe and effective profile for facial rejuvenation, providing significant aesthetic and structural improvements with long-lasting results. It offers a promising option for addressing the challenges of skin aging.